Search Results

1 - 10 of 68 items :

  • "autologous stem cell transplantation" x
Clear All

mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006; 24(16):2480-2489. 4. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90(8):2978-2986. 5. Isidori A, Bonifazi F, Visani G, et al. Autologous stem cell transplantation for acute myeloid patients in first complete remission: a 10-year follow-up study of 118 patients

relapsed FL patients. 4 In a Cochrane review in 2012, the authors demonstrated that high dose treatment (HDT) with autologous stem cell transplantation (ASCT) improves the progressionfree survival in comparison with chemotherapy or immuno-chemotherapy in previously untreated patients with FL, but does not prolong the OS. 5 There is also evidence that HDT with ASCT brings benefits to patients with relapsed FL. 5 , 6 A consensus was made in 2013 by the European Group for Blood and Marrow Transplant stating that the SCT is appropriate in patients with first chemo

–7) Number of involved extra-nodal areas (median, range) 1 (0–5) Clinical stage; no, % I 4 (7) II 8 (14) III 12 (21) IV 38 (66) Age-adjusted IPI risk; no, % Low 4 (7) Low-intermediate 12 (21) High-intermediate 40 (69) High 2 (3) B symptoms; no, % 34 (59) Rituximab containing regimen pre-ASCT; no, % 50 (86) Radiotherapy prior ASCT; no, % 21 (36) ASCT – autologous stem cell transplantation; B2M – beta2microglobulin; DLBCL – diffuse large B-cell lymphoma; IPI – international prognostic index; LDH – lactate dehydrogenase Treatment Induction treatment includes R-CHOP regimen (n

REFERENCES 1. Hübel K, de la Rubbia J, Azar N, et al. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. Eur J Haematol . 2015;94:12-22. 2. Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol . 2017;29:455-459. 3. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a


Stem cells are undifferentiated cells that can divide and become differentiated. Hematopoietic stem cells cannot transform into new stem cells such as cardiomyocytes or new heart valves, but they act through paracrine effects, by secreting cytokines and growth factors that lead to an increase in contractility and overall improved function. In this case report, we present how autologous stem cell transplantation can bring two major benefits: the first refers to hematological malignancy and the second is about the improvement of the heart condition. We present the case of a 60-year-old patient diagnosed with multiple myeloma suffering from a bi-valve severe condition in which autologous stem cell transplantation led to the remission of the patient’s malignant disease and also improved the heart function.

References 1. Attal M, Harouseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide imporves survival in patinets with multiple myeloma. Blood . 2006;108:3289-3294. 2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemotherapy for multiple myeloma: Final results of a phase III US intergroup trail S9321. J Clin Oncol . 2006;24:929-936. 3. van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood . 2014;124:328-333. 4. Koreth J, Clutler CS, Djulbegovic B, et al. High


We present the method of immunomagnetic stem cell separation with the ISOLEX 300i device (Isolex® 300i Magnetic Cell Selection System, Nextell Therapeutics Inc. Irvine California 21618 USA) and the results obtained using this method in patients admitted to the Hematology and Bone Marrow Transplantation Clinic of Tîrgu Mureş, Romania. Cell selection has a great importance in separating stem cells from tumor cells, therefore contributing to the success of autologous stem cell transplantation.

Introduction Graft-versus-host disease (GVHD) after autologous stem cell transplantation (ASCT) is a rare complication, but it can have a major impact on disease course and survival. Autologous GVHD is thought to occur in approximately 5% of transplanted patients [ 1 ]. Acute GVHD (aGVHD) is usually reported after allogeneic stem cell transplantation (allo-SCT) and is caused by donor T-cell recognition of recipients’ minor histocompatibility antigens followed by organ-specific attack [ 2 , 3 ]. However, in the context of ASCT, the pathomechanism of GVHD remains

primary mediastinal large B-cell lymphoma the routine usage of PET-CT scan is not validated and further prospective studies are warranted. 3 Still, the primary mediastinal lymphomas are like the diffuse large B cell lymphomas aggressive lymphomas with high proliferation rate and the PET-CT should supposedly be an adequate diagnostic procedure both for staging and response evaluation purposes. Our patients after autologous stem cell transplantation In our observation through past few years, we found three different cases of pulmonary granulomatosis and sarcoidosis in


Plasma cell leukemia (PCL) is one of the most aggressive monoclonal gammopathies, being characterized by the presence of more than 20% of plasma cells in the peripheral blood and an absolute number of these cells of more than 2×109, with different morphology, from young elements to mature cells. The incidence of PCL varies between 2–4% among multiple myeloma (MM) patients. In comparison with MM, PCL appears more often in younger patients. The following article describes the case of a 49-year-old female patient diagnosed with PCL which needed urgent control of the clinical manifestations due to its irreversible complications. Urgent autologous stem cell transplantation is recommended in this group of patients.